Summary
PHOSPHO1, a new member of the haloacid dehalogenase superfamily, has recently been implicated in the mineralization process in both osteoblasts and chondrocytes. In this study we describe the identification of a novel, alternatively spliced PHOSPHO1 transcript (PHOSPHO1-3a). This transcript contains the 3 exons of the previously published variant, however exon 3 contains a retained, 127bp section of intron 2. This forms an in-frame start site, producing an open reading frame of 879bp and predicting a protein of 292 amino acids. The novel 40 amino acid N-terminal region of PHOSPHO1-3a contains a relatively strong secretory signal, however all three domains of the HAD superfamily are retained in exon 3. The expression of this splice variant was confirmed in both human and mouse osteoblast-like cells and also in the chondrogenic ATDC5 cell line. The data within this study indicates a possible function relating to chondrocyte differentiation/mineralization as with the previously published variant.
Introduction
PHOSPHO1 is a phosphatase enzyme belonging to the HAD superfamily of hydrolases, which has been implicated in the generation of phosphate (Pi) for skeletal mineralization [1] . Initially Phospho1 gene studies were done in the chicken (Gallus gallus), however since then EST sequence database entries have been identified corresponding to human and murine Phospho1 which have been subsequently amplified and cloned [2] . These transcripts have a 94% identity to each other and are 62% identical to chick Phospho1. The human and murine Phospho1 genes lie within approximately 7.4Kb regions on HSA17q21.32 and distal MMU11 respectively, are flanked by the ACLY and GH1 loci, and exhibit conservation of synteny with part of GGA27. Using genetic linkage analysis, chick Phospho1 was mapped to the syntenic region on GGA27 [2] . This strongly suggests that the Phospho1 loci on HSA17 and MMU11 are orthologous to the Phospho1 gene originally identified in the chick.
Phospho1 has since been identified in a number of species including rat, zebrafish and puffer fish through EST analysis [3] .
PHOSPHO1 has been shown to have a high specific phosphohydrolase activity toward phosphoethanolamine (PEA) and phosphocholine (PCho) substrates [4] . PEA and PCho are involved in the biosynthesis of phosphatidylethanolamine and phosphatidylcholine, respectively, and form the polar headgroups of phospholipids in biological membranes. Both PEA and PCho levels are controlled in vivo by the expression of CTP-dependent cytidyltransferases, which catalyse the formation of CDP-ethanolamine and CDP-choline, respectively [5; 6] .
Phospho1 is expressed at high levels in bone tissue when compared with non-skeletal tissues in both chick and murine models [7; 8] . Immunolocalization studies have shown that PHOSPHO1 is specifically localized to mineralizing regions of skeletal tissue in both species [9] . In addition to the protein localization studies, Phospho1 transcript has also been localized in developing embryonic bones of the chick by in situ hybridization [1] . In this study the transcript of Phospho1 has been found to be expressed at sites destined for mineralization. Interestingly the transcript is present at these sites prior to overt signs of mineralization thereby providing support to the suggestion that PHOSPHO1 is involved in the initial stages of mineralization.
This expression/localization pattern suggests PHOSPHO1 is closely associated with the mineralization process and in particular the generation of Pi for hydroxyapatite production. This is an essential phase of mineral formation, not only for the precipitation with calcium but initially to raise the Pi/PPi ratio to a degree that is permissive to mineralization. This is due to PPi acting as a powerful inhibitor of HA formation [10; 11] . In addition, reduction of PHOSPHO1 activity through the use of newly discovered small molecule inhibitors causes a decrease in the capacity of MVs to calcify in vitro. These data indicate that PHOSPHO1 has a role in the mineralization process which is likely to be in the production of Pi for calcium phosphate precipitation.
In this study we now describe the discovery of a novel Phospho1 transcript which is expressed in human osteoblasts. In addition, we present data to suggest that both transcripts exist in murine osteoblasts and chondrocytes, suggesting a role in the differentiation/mineralization of these skeletal cells. Exon1-2-3bR 5'-CGGAGATGAGAATCACCTCG-3'; amplicon size 638bp and 511bp for Phospho1-3a and the previously published isoform respectively) were designed to allow amplification of exons created through alternative splice patterns (defined by EST analysis). Each transcript was amplified utilizing a 55°C annealing temperature and 200ng cDNA. The PCR products were then electrophoresed on a 2% agarose gel and purified using the Qiagen QiaQuick gel extraction kit. The PCR products were cloned directly into the pGEM-T-Easy vector. This plasmid is prelineralized and can ligate to the deoxyadenosine (A) at the 3´ ends of PCR products.
Materials and Methods

PCR Amplification of
The PCR product and plasmid were ligated in a 3:1 ratio using 100ng of PCR product.
This mixture was used to transform JM109 competent cells. Liquid cultures and plasmid minipreparations of individual clones were subsequently carried out. DNA sequencing of plasmids was carried out by the DNA sequencing facility at Dundee University.
Cell Culture
The ATDC5 chondrocyte cell line was obtained from the RIKEN cell bank (Ibaraki, Japan), and cells cultured at a density of 6000 cells/cm 2 in differentiation medium (DMEM:F12 (Invitrogen, Paisley, UK), 5% FCS (Invitrogen), 3x10 -8 M sodium selenite, 10µg/ml human transferrin (Sigma, Poole, UK) and 10µg/ml insulin (Sigma)). Cells were differentiated at 37 o C in a humidified atmosphere containing 5% CO 2 for up to 15 days. We and others have previously shown that from 8 days of differentiation, ATDC5 cells express the chondrocyte marker gene collagen type II, and by day 15, the cells display a terminally differentiating phenotype, with increased levels of collagen type X and aggrecan expression, and the formation of nodules [12; 13] . Some cultures were further differentiated for 28 days to induce mineralization in the presence of 10mM β-glycerol phosphate (βGP) and 50 µg/ml ascorbate-2-phosphate.
Mouse calvarial cells (wild-type Ob) were isolated from 3-day-old mice through sequential collagenase digestion. Calvarial cells were plated at a density of 20,000/cm 2 in alpha-MEM (Gibco, Paisley, UK) containing 10% FBS. MLO-A5 [14] cells were obtained from L.F. Bonewald (University of Missouri, Kansas City, MO) and cultured in a similar manner but seeded at 10,000/ cm 2 .
PCR of Genes During ATDC5 Differentiation
RNA was extracted and reverse transcribed as described above. Primers for 18s RNA were purchased from Applied Biosystems (Warrington, UK). Other primers were designed using the software programme Primer3 gene had a section of retained intron from intron 2 ( Figure 2 ). In order to investigate the possibility of an alternative splice variant, primers were designed to amplify a product containing exon one to three. Primers were designed to simultaneously amplify both the variant containing the novel exon -termed exon 3a, and the original isoform. The amplification products were cloned and sequenced. As seen in Figure 1B both splice variants can be amplified from SaOS-2 osteosarcoma cDNA, each identical apart from a 127bp exon found at the 5' region of exon 3 ( Figure 2B ). The novel transcript can be amplified both independently ( Figure 2B lane 2) and along with the previously published transcript ( Figure 2B lane 3) , depending on the position of the reverse primer. This novel variant is termed Phospho1-3a. This novel exon causes a frame shift, which in turn causes the initiation site from exon 2 to be lost and a novel start site to be created in exon 3a.
Consequently, an open reading frame of 879 nucleotides is formed, which can be translated into a protein of 292 amino acids. All three motifs which form the conserved active site from the HAD superfamily are conserved between both splice variants as they are all located within exon 3.
Expression of Phospho1-3a in differentiating chondrocytes
The Phospho1 splice variants were amplified using primers which crossed intron 2 and exon 3a of the Phospho1 gene, in order that both variants would be amplified together. As can be seen in figure 3A , 
PHOSPHO1 Protein Levels in Differentiating Cells
To analyze the effect of differentiating factors on the presence of PHOSPHO1 within mineralizing ATDC5 cells, the cells were cultured in the presence of 10 mM βGP and 50 µg/ml ascorbate-2-phosphate. Two forms of PHOSPHO1 (32 and 29KDa) were detected in each cell type corresponding to two splice variants from the Phospho1 gene, as seen in figure 3C . However, PHOSPHO1 appeared to be constitutively expressed and protein levels did not alter during the latter phase of matrix mineralization. Mineralization was evident by day 22 (data not shown).
Discussion
In this study, we identified a novel splice variant from the Phospho1 gene, named These spliceosomes recognise the boundary found between introns and exons, upon detection they catalyze the cutting out of intronic sequence and the joining of exons.
The recognition of specific splice sites relies on the presence of conserved intronic dinucleotides at the 5' (donor) and 3' (acceptor) exon-intron boundaries. However further sequences around the splice site are required for proper splicing [17] .
PHOSPHO1 has been shown to be involved in the mineralization process through the production of Pi for hydroxyapatite crystal formation. Its expression is restricted to cells of the skeleton where it has been shown to be highly expressed by both mineralizing chondrocytes and osteoblasts [7; 8; 9] . Within the epiphyseal growth plate, PHOSPHO1 protein has been located to prehypertrophic chondrocytes and absent from both proliferating and hypertrophic regions [8; 9] . This observation suggests that PHOSPHO1 has a role in the early stages of matrix mineralization. To analyse whether Phospho1-3a is differentially expressed during these stages the murine chondrogenic ATDC5 cell line was induced to differentiate from a proliferating to a terminally differentiated phenotype. Both Phospho1 transcripts were identified during this process at an apparent equal expression; however a modest increase in expression levels was noted over time, which is in agreement with Chen et al (2005) [18] . This is similar to another haloacid dehalogenase -like enzyme, Sarco/endoplasmic reticulum-type calcium transport ATPase 2, where a novel splice variant was identified to be involved in monocyte differentiation [19] . This splice variant, which is formed in a similar fashion to Phospho1-3a -through an inclusion of a small section of intronic sequence at the 3' region of the transcript, is upregulated during differentiation. As with PHOSHO1-3a the novel variant of SERCA2 is modulated in a similar fashion as the major isoform. This suggests that the novel splice variant from the Phospho1 gene may be involved in chondrogenic differentiation from a proliferating to hypertrophic phenotype along with the previously published isoform.
As Phospho1 has been implicated in the mineralization process, ATDC5 cells were induced to mineralize through the addition of βGP and ascorbate-2-phosphate for a period of 28 days. However, upon analysis of PHOSPHO1 protein levels directly pre and proceeding (detectable) matrix mineralization, the transcripts appear to be constitutively expressed, although the larger, novel Phospho1-3a is expressed at a higher level than the previously published variant, suggesting a possible synergy between the two isoforms. Similarly, the HAD enzyme epoxide hydrolase-2 has three published isoforms which differ in their N terminal regions only [20; 21] . All three isoforms are closely linked to the ovulation process, however exact functions for these
variants have yet to be identified. It is therefore possible that this is also the case with variants of Phospho1 and the mineralization process.
Phospho1 expression has been documented in alternative tissues such as heart and bone marrow, although at considerably lower levels [8] . The identification of the splice variant Phospho1-3a may suggest alternative functions in tissues other than bone. Interestingly, PHOSPHO1 has also been shown to be able to cleave PCho, the hydrolysis of which has been studied in hamster heart and has been shown to be catalysed by an unidentified enzyme [22] .
Recently PHOSPHO1 has been directly implicated in phase one of matrix vesicle mineralization [8] . This process involves the intra-vesicular formation of hydroxyapatite crystal and is critical for normal bone growth and maintenance. The identification of a novel splice variant from this gene may serve to provide further insights into this process or perhaps provide a means for Pi or PEA/Cho production in distinct sites. However, elucidation of the precise function and location of Phospho1-3a would first need to be established. 
